Bioinformatics and Biology Insights

ORIGINAL RESEARCH

Bioinformatics and Gene Network Analyses of the Swine Mammary Gland Transcriptome during Late Gestation

Wangsheng Zhao1,2,*, Khuram Shahzad2,3,*, Mingfeng Jiang4, Daniel E. Graugnard2, Sandra L. Rodriguez-Zas2,3, Jun Luo1, Juan J. Loor2,3,5 and Walter L. Hurley2

1College of Animal Science and Technology, Northwest Agricultural and Forestry University, YangLing, Shaanxi, China. 2Department of Animal Sciences, University of Illinois Urbana-Champaign, IL, USA. 3Illinois Informatics Institute, University of Illinois Urbana-Champaign, IL, USA. 4Sichuan Key Laboratory of Conservation and Utilization of Animal Genetic Resources in Tibetan Plateau, College of Life Science and Technology, Southwest University for Nationalities, China. 5Division of Nutritional Sciences, University of Illinois Urbana-Champaign, IL, USA. *These authors contributed equally. Corresponding authors email: luojun@nwsuaf.edu.cn; jloor@illinois.edu

Abstract: We used the newly-developed Dynamic Impact Approach (DIA) and gene network analysis to study the sow mammary transcriptome at 80, 100, and 110 days of pregnancy. A swine oligoarray with 13,290 inserts was used for transcriptome profiling. An ANOVA with false discovery rate (FDR < 0.15) correction resulted in 1,409 genes with a significant time effect across time comparisons. The DIA uncovered that Fatty acid biosynthesis, Interleukin-4 receptor binding, Galactose metabolism, and mTOR signaling were among the most-impacted pathways. IL-4 receptor binding, ABC transporters, cytokine-cytokine receptor interaction, and Jak-STAT signaling were markedly activated at 110 days compared with 80 and 100 days. Epigenetic and transcription factor regulatory mechanisms appear important in coordinating the final stages of mammary development during pregnancy. Network analysis revealed a crucial role for TP53, ARNT2, E2F4, and PPARG. The bioinformatics analyses revealed a number of pathways and functions that perform an irreplaceable role during late gestation to farrowing.

Keywords: systems biology, transcriptomics, mammary gland, sow, dynamic impact approach

Bioinformatics and Biology Insights 2013:7 193–216
doi: 10.4137/BBI.S12205

This article is available from http://www.la-press.com.

© the author(s), publisher and licensee Libertas Academica Ltd.

This is an open access article published under the Creative Commons CC-BY-NC 3.0 license.
Introduction

Milk production by the lactating sow is a major limiting factor for the development of the neonatal pig. The mammary gland of the sow undergoes significant development during gestation and lactation. Development of the mammary gland is particularly dramatic during the final 1/3 of the gestation period when the gland undergoes rapid morphogenesis and expansion of parenchymal tissue, as well as initiation of the early stage of lactogenesis and colostrigenesis just prior to parturition. The physiological adaptations marking this period are a consequence of shifting profiles of gene expression. Characterizing the role of genes involved in metabolic and signaling pathways during this period will provide a more detailed understanding of how the mammary gland undergoes this structural and functional development.

Transcriptomic studies provide highly-effective approaches to unravel complex biological behaviors at a genome-wide level. Longitudinal studies of transcriptome profiling data are of particular value in providing a detailed view of physiological adaptations in tissues. High-throughput technologies play a key role in understanding physiological states by analyzing the data obtained through pre-designed time course experiments. In addition, functional genomics studies provide a means of identifying new connections and interactions among the pathways, regulatory networks and structural organizations that underlie the function of tissues. Although previous studies using transcriptional profiling techniques have provided some preliminary insights into the differential expression of genes in sow mammary glands during the peripartum period, our understanding of differentially expressed genes (DEG) and metabolic or signaling pathways in mammary tissue in that species is limited.

KEGG is a biological database comprised of systematic, genome and chemical information using a combination of 19 other databases. The bioinformatics framework of DAVID relies principally on the overrepresented approach (ORA), and uses large gene lists for biological interpretation. Together, both tools and the Dynamic Impact Approach (DIA) provide a better option as compared to other traditional analysis approaches, which mainly rely on a reductionist approach and are inadequate for functional analysis of time-course experiments. Thus, compared with ORA, the DIA analysis captures the well-established and important biological features of the mammary gland during pregnancy.

In this study, we explored the role of biological pathways during late gestation in the sow by analyzing transcriptomics data using the DIA previously developed by our group. The DIA uses manually-curated reference pathways from Kyoto Encyclopedia of Genes and Genomes (KEGG) and Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics resources. The objective of this study was to undertake an integrated functional genomics study of the swine mammary gland transcriptome during late gestation by means of DIA and to highlight the role of its essential biological pathways.

Materials and Methods

Animal sampling and RNA extraction

All procedures for animal treatments were performed by following the guidelines approved by the University of Illinois Institutional Animal Care and Use Committee. 15 cross-bred primiparous gilts in late gestation were used for this study. Gilts were killed by exsanguination at the University of Illinois Meat Science Laboratory on day 80 (n = 5), 100 (n = 5) or 110 (n = 5) of gestation. Only tissue from gilts with at least 4 normal fetuses was used. Mammary glands were removed at slaughter and parenchymal tissue dissected from the central portion of the fourth anterior gland (previously observed to be the most developed gland during late pregnancy in primiparous gilts).

After sample collection and storage at −80 °C, the ribonucleic acid (RNA) was extracted using ice-cold Trizol (Invitrogen Corp., San Diego, CA). Agarose gel electrophoretic analysis of 28S and 18S rRNA was performed to assess the integrity of RNA. The purity and concentration of RNA were assessed using the NanoDrop ND-1000 spectrophotometer and deemed to be high enough to carry out microarray hybridization. A swine oligonucleotide microarray (70 mer) containing 13,290 functional hits was used for transcript profiling. A dye-swap reference design was conducted using three time points (80, 100, and 110) during late pregnancy according to procedures published previously. The array annotation was based on similarity searches using BLASTN and
BLASTX\textsuperscript{20} against human, mouse and pig UniGene databases, the human genome, and pig TIGR.\textsuperscript{21}

**Statistical analysis**

Data were normalized for dye and array effects before statistical analysis as previously described.\textsuperscript{19} Microarray spots with median intensity standard deviation above the median of the background were applied as filters in order to ensure high-quality data. The data were analyzed using a PROC MIXED model of SAS.\textsuperscript{19} The resulting \(P\)-values were adjusted according to the Benjamini and Hochberg’s correction method.\textsuperscript{22} An ANOVA with a false discovery rate (FDR) correction resulted in 10.6\% (1,409) DEG with a time effect (FDR < 0.15). The fold-change (FC) values were calculated using relative time points. Figure 1 contains the DEG at the 3 time point comparisons (namely, 100 versus (vs.) 80, 110 vs. 80, and 110 vs. 100 d). Tables 1–6 contain information on DEG that had a fold-change greater or lower than 2-fold at the 3 time point comparisons. The entire list of DEG can be found in Additional File 1.

**Dynamic impact approach and enrichment analysis (DIA)**

The newly developed DIA and the well-established DAVID bioinformatics resource were used to analyze the gene expression data. DIA uses the systems information from the KEGG database and ranks pathways based on their overall impact values across different time points. The detailed methodology of DIA analysis is described in.\textsuperscript{23} The DIA calculates the overall impact and flux (direction of impact) of biological pathways. For this purpose, the whole dataset (Additional File 1: sheet ‘Dataset’) with Entrez gene IDs, FDR, FC, and raw \(P\)-values of each time comparison were uploaded to calculate the impact and flux. An overall cut-off FDR < 0.15 and \(P\)-value < 0.05 between time points were applied as thresholds. The resultant summary of the DIA KEGG pathways (encompassing categories and subcategories) is shown in Figure 2. The DIA resulted in 195 biologically-impacted KEGG pathways (Additional File 2: sheet ‘DIA KEGG’). For enrichment analysis, the KEGG pathways were downloaded from the DAVID database with enrichment \(P\)-values and Benjamini-Hochberg FDR values (Additional File 4).

**Gene ontology (GO) term analysis**

GO terms such as biological process (BP), cellular components (CC), and molecular functions (MF) were downloaded from the DAVID database and were analyzed using DIA. For this purpose, a multigene list of both up and down regulated Entrez gene IDs was uploaded to the DAVID database.\textsuperscript{24} For background information, we uploaded Homo sapiens Entrez gene IDs corresponding to our customized oligo array.

**KEGG pathways visualization**

KegArray tool\textsuperscript{25} was used to analyze the KEGG pathways among DEG. For this purpose, a list of Entrez gene ID’s with their respective FC values was uploaded for each time comparison. An FC cut-off value of 1 was applied as a threshold criterion. The results are listed in Additional File 3 and are discussed in the sections below.

**Clustering results**

The ‘Functional Annotation Clustering’ results were also downloaded from the DAVID database. To select the most significant results, we applied an enrichment score cutoff criterion of \(≥ 1.3\). The clustering results can be found in Additional File 4.

**Gene network analysis**

This analysis was performed as describe previously by Piantoni et al.\textsuperscript{26} Briefly, we used Ingenuity Pathway Analysis\textsuperscript{6} (IPA) to identify transcription regulators and their networks with other genes within the list of significant DEG at each of the 3 time comparisons.
Table 1. List of DEG (FDR < 0.15 and raw \(P < 0.10\)) with 2-fold or greater upregulation on day 100 vs. 80. The Entrez Gene ID for each gene can be found in Additional File 1.

| Gene symbol | Description                                           | Fold  |
|-------------|-------------------------------------------------------|-------|
| TF          | Transferrin                                           | 4.51  |
| HPR         | Haptoglobin-related protein                           | 4.03  |
| TTN         | Titin                                                | 3.61  |
| UGP2        | UDP-glucose pyrophosphorylase 2                       | 3.52  |
| OGFOD3      | 2-oxoglutarate and iron-dependent oxygenase domain containing 3 | 3.47  |
| VIPR1       | Vasoactive intestinal peptide receptor 1              | 3.17  |
| DDX42       | DEAD (Asp-Glu-Ala-Asp) box polypeptide 42             | 3.13  |
| KIAA1755    | KIAA1755                                              | 3.10  |
| PROC        | Protein C (inactivator of coagulation factors Va and VIIla) | 2.93  |
| KLB1        | Kallikrein B, plasma (Fletcher factor) 1               | 2.89  |
| TGD5        | TDP-glucose 4,6-dehydratase                          | 2.83  |
| PIGR        | Polymeric immunoglobulin receptor                     | 2.77  |
| PAX8        | Paired box gene 8                                     | 2.75  |
| C7          | Complement component 7                                | 2.73  |
| BTN1A1      | Butyrophilin, subfamily 1, member A1                  | 2.70  |
| NUDT7       | Nucleoside diphosphate-linked moiety X motif 7        | 2.69  |
| TXNDC17     | Thioredoxin-like 5                                    | 2.67  |
| RARB        | Retinoic acid receptor, beta                          | 2.66  |
| SALL2       | Sal-like 2 (Drosophila)                               | 2.63  |
| LSP1        | Lymphocyte-specific protein 1                         | 2.62  |
| ABCG2       | ATP-binding cassette, sub-family G (WHITE), member 2  | 2.62  |
| MST1        | Macrophage stimulating 1 (hepatocyte growth factor-like) | 2.56  |
| CPS1        | Carbamoyl-phosphate synthetase 1, mitochondrial       | 2.52  |
| ARRDC3      | Arrestin domain containing 3                         | 2.49  |
| S100G       | S100 calcium binding protein G                        | 2.47  |
| ACY1        | Aminoacylase 1                                        | 2.45  |
| LHX9        | LIM homeobox 9                                        | 2.41  |
| PDZD3       | PDZ domain containing 3                               | 2.37  |
| KRT17       | Keratin 16                                            | 2.36  |
| SPTBN1      | Spectrin, beta, non-erythrocytic 1                    | 2.35  |
| MYH4        | Myosin, heavy chain 4, skeletal muscle                | 2.34  |
| NNAT        | Neuronatin                                            | 2.32  |
| RNF11       | Ring finger protein 11                                | 2.32  |
| COL8A1      | Collagen, type VIII, alpha 1                          | 2.31  |
| B3GALTL     | Beta 1,3-galactosyltransferase-like                    | 2.30  |
| KLC4        | Kinesin light chain 4                                 | 2.28  |
| MECP2       | Methyl CpG binding protein 2 (Rett syndrome)          | 2.28  |
| FTCD        | Formiminotransferase cyclodeaminase                   | 2.27  |
| WHSC1L1     | Wolf-Hirschhorn syndrome candidate 1-like 1           | 2.26  |
| CYP2E1      | Cytochrome P450, family 2, subfamily E, polypeptide 1 | 2.25  |
| UVRAG       | UV radiation resistance associated gene                | 2.25  |
| TMCO5A      | Transmembrane and coiled-coil domains 5A              | 2.20  |
| IGJ         | Immunoglobulin j polypeptide                          | 2.19  |
| TNK1        | Tyrosine kinase, non-receptor, 1                      | 2.17  |
| PRRC2C      | Proline-rich coiled-coil 2C                           | 2.17  |
| EEPD1       | Endonuclease/exonuclease/phosphatase family domain containing 1 | 2.15  |
| FBP1        | Fructose-1,6-bisphosphatase 1                         | 2.15  |
| FMO1        | Flavin containing monoxygenase 1                      | 2.14  |
| ACACA       | Acetyl-Coenzyme A carboxylase alpha                   | 2.13  |
| IER5        | Immediate early response 5                            | 2.12  |
| MT1A        | Metallothionein 1A (functional)                       | 2.10  |
| FLRT2       | Fibronectin leucine rich transmembrane protein 2      | 2.09  |
| TESK1       | Testis-specific kinase 1                              | 2.08  |

(Continued)
Table 1. (Continued)

| Gene symbol | Description                                                                 | Fold |
|-------------|------------------------------------------------------------------------------|------|
| IDH2        | Isocitrate dehydrogenase 2 (NADP+), mitochondrial                           | 2.08 |
| HHIPL2      | HHIIP-like 2                                                                  | 2.07 |
| CLEC18C     | C-type lectin domain family 18, member C                                      | 2.06 |
| GREB1       | GREB1 protein                                                                 | 2.06 |
| ITGA2B      | Integrin, alpha 2b                                                           | 2.05 |
| PLOD3       | Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3                           | 2.05 |
| PDIA4       | Protein disulfide isomerase family A, member 4                                | 2.04 |
| AKR1B1      | Aldo-keto reductase family 1, member B1 (aldose reductase)                   | 2.02 |
| ERLIN2      | SPFH domain family, member 2                                                  | 2.02 |
| ATF5        | Activating transcription factor 5                                             | 2.01 |
| WDR26       | WD repeat domain 26                                                           | 2.01 |
| CELF1       | CUGBP, Elav-like family member 1                                              | 2.00 |

Software features and the IPA knowledge base were used for the analysis.

Results

Coverage of microarray elements and DEG

Out of 13,290 unique spots on the microarray, a total of 12,313 oligo IDs were annotated with human Entrez IDs which constituted approximately 92.65% of the total coverage. To identify the longitudinal transcriptional gene response during late pregnancy we relied on DEG between 100 vs. 80, 110 vs. 80, and 110 vs. 100 days. The 100 vs. 80 days comparison represents the difference in gene expression patterns between the relatively immature mammary gland at approximately 34 days prior to parturition and the substantially more developed gland at about 14 days prepartum in the primigravid gilt.\(^3,5\) The 110 vs. 80 days comparison represents the difference in gene expression patterns between the immature gland and the gland that is near full term at about 4 days prepartum. In contrast, the 110 vs. 100 days comparison represents the difference in mammary tissue between a time of rapid growth and limited functional differentiation at 100 days of gestation and the time at 110 days when the gland continues growing but also is entering into the functional differentiation stages associated with lactogenesis.

At \(P \leq 0.05\) and \(\text{FDR} \leq 0.15\), a total of 951 genes (348 up- and 603 down-regulated genes) at 100 vs. 80 days, 878 genes (336 up- and 542 down-regulated genes), and 221 genes (132 up- and 89 down-regulated genes) genes were differentially expressed (Fig. 1). Among these, only 701, 528 and 207 genes, respectively, were annotated with human Entrez gene IDs. For the 100 vs. 80 days and 110 vs. 80 days comparisons more genes were down-regulated as compared to up-regulated.

Overall summary of KEGG categories

Figure 2 provides a summary of KEGG categories (also see Additional File 2: Sheet ‘KEGG Summary’). The ‘Metabolism’ (M) category was up-regulated, whereas the ‘Genetic Information Processing’ category (GIP), ‘Environmental Information Processing’ category (EIP), ‘Cellular Processes’ category (CP) and ‘Organismal systems’ category (OS) were down-regulated in the 100 vs. 80 days comparison and the CP and OS categories were down-regulated in the 110 vs. 80 days comparison. In contrast, all categories and sub-categories were up-regulated in the 110 vs. 100 days comparison (Fig. 2).

Of the Metabolism sub-categories, metabolism of carbohydrate, energy, lipid, amino acids, cofactors and vitamins, and terpenoids and polyketides were up-regulated in the 100 vs. 80 days comparison. This up-regulated state was also observed in the 110 vs. 80 days comparison for metabolism of carbohydrate, energy, lipid, cofactors and vitamins, and terpenoids and polyketides, but not for amino acid metabolism. Expression of pathways associated with metabolism of carbohydrate, energy, lipid, and cofactors and vitamins continued to be up-regulated in the 110 vs. 100 days comparison, although with a more limited impact value. In contrast, expression pathways associated with metabolism of amino acids, terpenoids and...
Table 2. List of DEG (FDR < 0.15 and raw $P < 0.10$) with 2-fold or greater upregulation on day 110 vs. 80. The Entrez Gene ID for each gene can be found in Additional File 1.

| Gene symbol | Description                                                                 | Fold  |
|-------------|------------------------------------------------------------------------------|-------|
| ABCB11      | ATP-binding cassette, sub-family B (MDR/TAP), member 11                      | 9.75  |
| SLX1B       | SLX1 structure-specific endonuclease subunit homolog B (S. cerevisiae)      | 6.02  |
| DEAF1       | Deformed epidermal autoregulatory factor 1 (Drosophila)                     | 5.82  |
| ZNF362      | FLJ25476 protein                                                            | 5.63  |
| NDUF5       | NADH dehydrogenase (ubiquinone) Fe-S protein 5                             | 5.59  |
| MTHFR       | 5,10-methylenetetrahydrofolate reductase (NADPH)                           | 5.56  |
| CHERP       | Calcium homeostasis endoplasmic reticulum protein                           | 5.37  |
| LALBA       | Lactalbumin, alpha                                                          | 5.31  |
| KLHDC8A     | Kelch domain containing 8A                                                 | 5.09  |
| CXXC1       | CXXC finger 1 (PHD domain)                                                  | 4.85  |
| SEPT9       | Septin 9                                                                    | 4.60  |
| RWDD2A      | RWD domain containing 2                                                     | 4.54  |
| IL4         | Interleukin 4                                                               | 4.39  |
| ACO2        | Aconitase 2, mitochondrial                                                  | 4.37  |
| APBB3       | Amyloid beta (A4) precursor protein-binding, family B, member 3             | 4.21  |
| FBXW9       | F-box and WD-40 domain protein 9                                            | 4.18  |
| ACSBG2      | Acyl-CoA synthetase bubblegum family member 2                              | 4.08  |
| KLHDC8B     | Kelch domain containing 8B                                                  | 3.96  |
| HPR         | Haptoglobin-related protein                                                 | 3.94  |
| ZNF474      | Zinc finger protein 47                                                      | 3.85  |
| GPD1        | Glycerol-3-phosphate dehydrogenase 1 (soluble)                              | 3.64  |
| PIGR        | Polymeric immunoglobulin receptor                                          | 3.47  |
| LRC8A       | Leucine rich repeat containing 8 family, member A                           | 3.38  |
| MBD5        | Methyl-CpG binding domain protein 5                                          | 3.36  |
| RAD54L      | RAD54-like (S. cerevisiae)                                                  | 3.36  |
| LSP1        | Lymphocyte-specific protein 1                                               | 3.33  |
| SIX6        | Sine oculis homeobox homolog 6 (Drosophila)                                 | 3.22  |
| RAB2A       | RAB2, member RAS oncogene family                                           | 3.06  |
| HDAC6       | Histone deacetylase 6                                                       | 3.04  |
| KRT17       | Keratin 12                                                                  | 3.00  |
| CRELD2      | Cysteine-rich with EGF-like domains 2                                       | 2.99  |
| CSNK1A1     | Casein kinase 1, alpha 1                                                    | 2.94  |
| CCDC159     | Coiled-coil domain containing 159                                           | 2.90  |
| HHIP2       | HHIP-like 2                                                                 | 2.86  |
| MARCH3      | Membrane-associated ring finger (C3HC4) 3                                  | 2.85  |
| RLNS        | Renalase, FAD-dependent amine oxidase                                       | 2.81  |
| AP2B1       | Adaptor-related protein complex 2, beta 1 subunit                          | 2.73  |
| SPRRB       | Signal recognition particle receptor, B subunit                             | 2.69  |
| SSNA1       | Sjogren’s syndrome nuclear autoantigen 1                                   | 2.66  |
| BTN1A1      | Butyrophilin, subfamily 1, member A1                                        | 2.65  |
| RNF11       | Ring finger protein 11                                                       | 2.63  |
| ITPB4       | Integrin, beta 4                                                            | 2.61  |
| MAP2K5      | Mitogen-activated protein kinase kinase 5                                   | 2.57  |
| FAM13C      | Family with sequence similarity 13, member C                                | 2.56  |
| KLF9        | Kruppel-like factor 9                                                       | 2.45  |
| C20orf24    | Chromosome 20 open reading frame 24                                         | 2.39  |
| SPTBN1      | Spectrin, beta, non-erythrocytic 1                                          | 2.37  |
| RARB        | Retinoic acid receptor, beta                                                | 2.36  |
| COL8A1      | Collagen, type VIII, alpha 1                                                | 2.28  |
| TARP        | TCR gamma alternate reading frame protein                                   | 2.26  |
| ZNF197      | Zinc finger protein 197                                                     | 2.24  |
| ARRDC3      | Arrestin domain containing 3                                                | 2.24  |
| EPS15       | Epidermal growth factor receptor pathway substrate 15                      | 2.24  |

(Continued)
polyketides was unchanged in that latter comparison. Carbohydrate metabolism consistently had the greatest impact factor in each day comparison.

Transcription, translation and replication and repair sub-categories of GIP and the signal transduction sub-category of EIP each were down-regulated in the 100 vs. 80 days and 110 vs. 80 days comparisons, but were up-regulated in the 110 vs. 100 days comparison. In contrast, the folding, sorting and degradation sub-category of GIP was consistently up-regulated in each comparison, as was the membrane transport and signaling molecules and interaction sub-categories of EIP.

All sub-categories of CP and OS (except environmental adaptation) were strongly down-regulated in the 100 vs. 80 days comparison. This expression relationship was also seen in the 110 vs. 80 days comparison, with the exception of the immune system sub-category of the OS category, which was up-regulated. All sub-categories of the CP and OS categories were up-regulated in the 110 vs. 100 days comparison except for sensory system, which was not different in that comparison.

Most impacted KEGG pathways
The DIA analysis provides an evaluation of the impact of pathways within sub-categories of KEGG (Additional File 2: Sheet ‘DIA KEGG’). The overall most-impacted pathway was fatty acid biosynthesis. This impact was particularly strong in the 100 vs. 80 days comparison, continued to be a high impact in the 110 vs. 80 days comparison, and then remained unchanged in the 110 vs. 100 days comparison. Galactose metabolism, one carbon pool by folate, glyoxalate and dicarboxylate metabolism, and linoleic acid metabolism were among the 25 overall most impacted pathways among the metabolism sub-categories.

The intestinal immune network for the IgA production pathway of the Immune System was found to be highly impacted in the overall analysis, with the highest impacts in 110 vs. 80 days and 110 vs. 100 days comparisons. In addition, 5 pathways of the Immune System Diseases sub-category were among the 25 most impacted pathways in the DIA analysis (Additional File 2: Sheet ‘DIA KEGG’).

Several other pathways were identified as overall highly impacted by the DIA analysis. The ECM-receptor interaction pathway of the Signaling Molecules and Interaction sub-category seemed to switch from up-regulation in the 100 vs. 80 days comparison, to down-regulation in the 110 vs. 80 days comparison, and back to up-regulation in the 110 vs. 100 days comparison. The vascular smooth muscle contraction pathway (circulatory System sub-category) and gap junction pathway (cell communication sub-category) were consistently down-regulated in the 100 vs. 80 days and 110 vs. 80 days comparisons, and then up-regulated in the 110 vs. 100 days comparison. In contrast, the ATP-binding
Table 3. List of DEG (FDR < 0.15 and raw $P < 0.10$) with 2-fold or greater upregulation on day 110 vs. 100. The Entrez Gene ID for each gene can be found in Additional File 1.

| Gene symbol | Description                                                                   | Fold |
|-------------|--------------------------------------------------------------------------------|------|
| BARD1       | BRCA1 associated RING domain 1                                                | 5.35 |
| SLX1B       | SLX1 structure-specific endonuclease subunit homolog B                       | 5.26 |
| STRADA      | STE20-related kinase adaptor alpha                                            | 5.12 |
| KLHDC8A     | Kelch domain containing 8A                                                    | 5.12 |
| CHERP       | Calcium homeostasis endoplasmic reticulum protein                           | 4.26 |
| DEAF1       | Deformed epidermal autoregulatory factor 1 (Drosophila)                      | 4.22 |
| UROC1       | Urocanase domain containing 1                                                | 4.02 |
| MTHFR       | 5,10-methylenetetrahydrofolate reductase (NADPH)                            | 3.70 |
| FLYWCH1     | FLYWCH-type zinc finger 1                                                    | 3.66 |
| ABCB11      | ATP-binding cassette, sub-family B (MDR/TAP), member 11                     | 3.51 |
| GPD1        | Glycerol-3-phosphate dehydrogenase 1 (soluble)                              | 3.37 |
| KLHDC8B     | Kelch domain containing 8B                                                   | 3.31 |
| ABCC11      | ATP-binding cassette, sub-family B (MDR/TAP), member 11                     | 3.01 |
| SHARPIN     | SHANK-associated RH domain interactor                                         | 2.98 |
| ZNF474      | Zinc finger protein 474                                                      | 2.93 |
| MRI1        | Methylthioribose-1-phosphate isomerase homolog                              | 2.86 |
| ACO2        | Aconitase 2, mitochondrial                                                   | 2.77 |
| ITGB4       | Integrin, beta 4                                                            | 2.72 |
| MST1        | Macrophage stimulating 1 (hepatocyte growth factor-like)                    | 2.64 |
| TGM3        | Transglutaminase 3 (protein-glutamine-gamma-glutamyltransferase)            | 2.61 |
| IL4         | Interleukin 4                                                               | 2.58 |
| CDC37       | Cell division cycle 37 homolog (S. cerevisiae)                              | 2.52 |
| MBD5        | Methyl-CpG binding domain protein 5                                          | 2.50 |
| MAP2K5      | Mitogen-activated protein kinase kinase 5                                   | 2.45 |
| RAB2A       | RAB2, member RAS oncogene family                                            | 2.38 |
| SPPL3       | Signal peptide peptidase like 3                                             | 2.36 |
| EPS15       | Epidermal growth factor receptor pathway substrate 15                       | 2.34 |
| ARHGAP17    | Rho GTPase activating protein 15                                             | 2.34 |
| SEZ6L       | Seizure related 6 homolog (mouse)-like                                       | 2.33 |
| SNORD88C    | Small nucleolar RNA, C/D box 88C                                            | 2.28 |
| ZNF197      | Zinc finger protein 197                                                      | 2.25 |
| DEF6        | Differentially expressed in FDCP 6 homolog (mouse)                         | 2.22 |
| SRRPRB      | Signal recognition particle receptor, B subunit                             | 2.20 |
| NOMO1       | NODAL modulator 1                                                           | 2.17 |
| SSNA1       | Sjogren's syndrome nuclear autoantigen 1                                    | 2.13 |
| CSNK1A1     | Casein kinase 1, alpha 1                                                     | 2.03 |
| AP2B1       | Adaptor-related protein complex 2, beta 1 subunit                           | 2.03 |
| DNAJB12     | DnaJ (Hsp40) homolog, subfamily B, member 12                               | 2.02 |

cassette (ABC) transporters pathway (membrane transport sub-category) and the protein export pathway (folding, sorting and degradation sub-category) were up-regulated or not different in the 100 vs. 80 days comparison, strongly up-regulated in the 110 vs. 80 days comparison and up-regulated in the 110 vs. 100 days comparison.

Interestingly, 4 pathways of the cardiovascular diseases sub-category were among the 25 most impacted sub-categories in the DIA analysis, including arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertropic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) and viral myocarditis. In each of the latter pathways, the highest impact factors were observed in the 100 vs. 80 days or 110 vs. 80 days comparisons.

From the KEGG pathways analyzed by the overrepresentation approach (ORA) as shown in Additional File 4 (at an FDR enrichment $P$-value of 0.05) it could be discerned that the vascular smooth muscle contraction and long-term potentiation pathways both were most significantly enriched and were down-regulated at 100 vs. 80 days. The ECM-receptor interaction pathway...
Table 4. List of DEG (FDR < 0.15 and raw \( P < 0.10 \)) with 2-fold or greater downregulation on day 100 vs. 80.

| Gene symbol | Description                                              | Fold  |
|-------------|----------------------------------------------------------|-------|
| ZNF692      | Zinc finger protein 692                                  | -2.82 |
| DSP         | Desmoplakin                                              | -2.47 |
| SOX4        | SRY (sex determining region Y)-box 4                    | -2.45 |
| STMN1       | Stathmin 1/oncoprotein 18                                | -2.35 |
| RANBP3      | RAN binding protein 3                                     | -2.35 |
| YIF1A       | Yip1 interacting factor homolog A (S. cerevisiae)        | -2.33 |
| COL5A2      | Collagen, type V, alpha 2                                | -2.31 |
| GNAQ        | Guanine nucleotide binding protein (G protein), q polypeptide | -2.30 |
| METAP2      | Methionyl aminopeptidase 2                               | -2.30 |
| CENPF       | Centromere protein F, 350/400ka (mitosin)                | -2.27 |
| POSTN       | Periostin, osteoblast specific factor                     | -2.27 |
| TRGJP       | TRGJP T cell receptor gamma joining P                     | -2.25 |
| H2AFZ       | H2A histone family, member Z                             | -2.25 |
| MDK         | Midkine (neurite growth-promoting factor 2)              | -2.20 |
| PTPN11      | Protein tyrosine phosphatase, non-receptor type 11       | -2.18 |
| PADI2       | Peptidyl arginine deiminase, type II                     | -2.18 |
| RCOR1       | REST corepressor 1                                        | -2.15 |
| MXRA7       | Matrix-remodelling associated 7                          | -2.15 |
| CYP2C18     | Cytochrome P450, family 2, subfamily C, polypeptide 18   | -2.11 |
| PRRC2B      | Proline-rich coiled-coil 2B                              | -2.10 |
| PDLIM5      | PDZ and LIM domain 5                                     | -2.09 |
| TUBA1C      | Tubulin, alpha 6                                         | -2.08 |
| ZCCHC3      | Zinc finger, CCHC domain containing 3                    | -2.08 |
| NAB1        | NGFI-A binding protein 1 (ERG1 binding protein 1)        | -2.07 |
| NPM1        | Nucleophosmin (nucleolar phosphoprotein B23, numatrin)   | -2.05 |
| G2E3        | G2/M-phase specific E3 ubiquitin protein ligase          | -2.05 |
| EGR1        | Early growth response 1                                  | -2.04 |
| CDC45       | Cell division cycle 45                                   | -2.03 |
| RPL15       | Ribosomal protein L15                                    | -2.03 |
| MAP1B       | Transcribed locus                                        | -2.02 |
| SS18        | Synovial sarcoma translocation, chromosome 18            | -2.02 |
| ATRX        | Alpha thalassemia/mental retardation syndrome X-linked   | -2.01 |
| ZNF136      | Zinc finger protein 44                                    | -2.01 |
| PPP1R12A    | Protein phosphatase 1, regulatory (inhibitor) subunit 12A | -2.01 |
| TUBA1C      | Tubulin, alpha 6                                         | -2.01 |
| NREP        | Neuronal regeneration related protein                     | -2.00 |

was up-regulated in the 100 vs. 80 days and 110 vs. 80 days comparisons (Additional File 2, DIA KEGG sheet; Additional File 3); gap junction and intestinal immune network for IgA production pathways both were up-regulated in the 110 vs. 100 days comparison (Additional File 2, DIA KEGG sheet). The cell cycle and neurotrophin signaling pathways both were down-regulated in the 100 vs. 80 days and 110 vs. 80 days comparisons (Additional File 2, DIA KEGG sheet), while the Jak-STAT signaling pathway was up-regulated in the 110 vs. 80 days comparison (Fig. 3). The complement and coagulation cascades pathway was up-regulated in the 100 vs. 80 days comparison. These pathways can also be explored in Additional File 3 which lists the pathways obtained from the KegArray tool.

Gene ontology (GO) and cluster analysis

The DIA analysis was used to evaluate GO terms under the 3 main GO classes, including Biological Processes (BP), Cellular Components (CC) and Molecular Function (MF), as summarized in Figure 4 and Additional File 2 (Sheets ‘GOTERM BP’, ‘GOTERM CC’ and ‘GOTERM MF’, respectively). Among the ten most-enriched BP, DNA double-strand break processing involved in repair via
Table 5. List of DEG (FDR < 0.15 and raw P < 0.10) with 2-fold or greater downregulation on day 110 vs. 80. The Entrez Gene ID for each gene can be found in Additional File 1.

| Gene symbol | Description                                                                 | Fold  |
|-------------|-----------------------------------------------------------------------------|-------|
| COL1A2      | Collagen, type I, alpha 2                                                   | -3.57 |
| COL1A1      | Collagen, type I, alpha 1                                                   | -3.55 |
| COL1A2      | Collagen, type I, alpha 2                                                   | -3.15 |
| RANBP3      | RAN binding protein 3                                                        | -3.09 |
| POSTN       | Periostin, osteoblast specific factor                                        | -2.93 |
| COL3A1      | Collagen, type III, alpha 1                                                 | -2.90 |
| ZNF692      | Zinc finger protein 692                                                     | -2.86 |
| DSP         | Desmoplakin                                                                 | -2.67 |
| SGSN3       | RUN and TBC1 domain containing 3                                            | -2.63 |
| SOX4        | SRY (sex determining region Y)-box 4                                        | -2.58 |
| H2AFZ       | H2A histone family, member Z                                                | -2.49 |
| EGR1        | Early growth response 1                                                     | -2.49 |
| GBP1P1      | Guanylate binding protein 1, interferon-inducible pseudogene 1             | -2.45 |
| H3F3B       | H3 histone, family 3B (H3.3B)                                               | -2.45 |
| ZFP36L1     | Zinc finger protein 36, C3H type-like 1                                     | -2.45 |
| OR1M1       | Olfactory receptor, family 1, subfamily M, member 1                         | -2.44 |
| C1orf55     | Chromosome 1 open reading frame 55                                          | -2.40 |
| UNC13C      | Unc-13 homolog C (C. elegans)                                               | -2.36 |
| NXNL2       | Chromosome 9 open reading frame 121                                         | -2.35 |
| TUBA1C      | Tubulin, alpha 6                                                            | -2.34 |
| OXTR        | Oxytocin receptor                                                           | -2.33 |
| C1GALT1     | Core 1 synthase, glycoprotein-N-acetylgalactosamin 3-beta-galactosyltransferase, 1 | -2.29 |
| RPL15       | Ribosomal protein L15                                                       | -2.28 |
| ELK3        | ELK3, ETS-domain protein                                                    | -2.28 |
| LAPTM4B     | Lysosomal associated protein transmembrane 4 beta                           | -2.26 |
| PADI2       | Peptidyl arginine deiminase, type II                                       | -2.25 |
| PPP4R1      | Protein phosphatase 4, regulatory subunit 1                                 | -2.23 |
| COL5A2      | Collagen, type V, alpha 2                                                   | -2.23 |
| HNRNP1H2    | Heterogeneous nuclear ribonucleoprotein H2                                 | -2.21 |
| ZFP36L1     | Zinc finger protein 36, C3H type-like 1                                     | -2.20 |
| METAP2      | Methionyl aminopeptidase 2                                                  | -2.18 |
| ARL6IP6     | ADP-ribosylation-like factor 6 interacting protein 6                        | -2.16 |
| HNRNP1PR    | Heterogeneous nuclear ribonucleoprotein R                                  | -2.14 |
| RPL39       | Ribosomal protein L39                                                       | -2.13 |
| TUBA1C      | Tubulin, alpha 6                                                            | -2.13 |
| FKBP3       | FK506 binding protein 3, 25 kDa                                             | -2.12 |
| SMTNL2      | Smoothelin-like 2                                                           | -2.12 |
| CALM2       | Calmodulin 2 (phosphorylase kinase, delta)                                  | -2.09 |
| PTPRF       | Protein tyrosine phosphatase, receptor type, F                              | -2.08 |
| C7orf60     | Chromosome 7 open reading frame 60                                          | -2.08 |
| RPL17       | Ribosomal protein L17                                                       | -2.06 |
| TK2         | Thymidine kinase 2, mitochondrial                                           | -2.05 |
| CEP135      | Centrosomal protein 135 kDa                                                 | -2.04 |
| PARP3       | Poly (ADP-ribose) polymerase family, member 3                              | -2.03 |
| HNRPD1      | Heterogeneous nuclear ribonucleoprotein D-like                             | -2.01 |
| HLA-A       | Major histocompatibility complex, class I, A                                | -2.00 |
Table 6. List of DEG (FDR < 0.15 and raw P < 0.10) with 2-fold or greater downregulation on day 110 vs. 100. The Entrez Gene ID for each gene can be found in Additional File 1.

| Gene symbol | Description | Fold |
|-------------|-------------|------|
| ARL6IP6     | ADP-ribosylation-like factor 6 interacting protein 6 | -3.26 |
| OGFOD3      | 2-oxoglutarate and iron-dependent oxygenase domain containing 3 | -2.60 |
| KLKB1       | Kallikrein B, plasma (Fletcher factor) 1 | -2.57 |
| NDRG1       | N-myc downstream regulated gene 1 | -2.26 |
| TBC1D13     | TBC1 domain family, member 13 | -2.24 |
| TDP2        | Tyrosyl-DNA phosphodiesterase 2 | -2.22 |
| ELK3        | ELK3, ETS-domain protein | -2.20 |
| UGP2        | UDP-glucose pyrophosphorylase 2 | -2.03 |

Single-strand annealing, connective tissue growth factor production, connective tissue growth factor biosynthetic process, and double-strand break repair via single-strand annealing each were only mildly changed in the 100 vs. 80 days comparison, but then strongly impacted and up-regulated in the 110 vs. 80 days and 110 vs. 100 days comparisons. Negative regulation of mRNA 3′-end processing was strongly impacted and up-regulated only in the 110 vs. 100 days comparison. Positive regulation of isotype switching to IgE isotypes was most strongly impacted and up-regulated in the 110 vs. 80 days comparison. Response to anoxia and ERK1 and ERK2 cascade were not changed in the 100 vs. 80 days comparison, however both became highly activated.

![Figure 2](http://www.genome.jp/kegg/pathway.html) Overall summary of the KEGG categories and sub-categories resulting from DIA analysis. Three time comparisons are shown viz., 100 vs. 80 d, 110 vs. 80 d and 110 vs. 100 d. Each time comparison consists of impact and flux. The impact values are shown in purple ranging from 0 (not impacted) to 15 (highly impacted), while flux values are represented from -10 (green = highly inhibited) to 10 (red = highly activated).
impacted and down-regulated in the 110 vs. 80 and 110 vs. 100 days comparisons.

Among the 10 most-enriched CC, the Six1-Six4 complex were not changed in the 100 vs. 80 days comparison, and then were highly impacted and up-regulated in the 110 vs. 80 and 110 vs. 100 days comparisons. Collagen type VIII and short-chain collagen were strongly impacted and up-regulated in the 100 vs. 80 and 110 vs. 80 days comparisons, with no differences observed in the 110 vs. 100 days comparison. In contrast, collagen type III was only impacted in the 110 vs. 80 days comparison when it was down-regulated. Glycerol-3-phosphate dehydrogenase complex and intercellular canaliculus both were not different in the 100 vs. 80 days comparison, then up-regulated in the 110 vs. 80 and 110 vs. 100 days comparisons. In contrast to the above, PCNA complex was highly impacted and down-regulated in the 100 vs. 80 days comparison, but not observed to be different in the other comparisons.

Of the ten most-enriched MF, 3 patterns emerged (Fig. 4). Crossover junction endodeoxyribonuclease activity, interleukin 4 receptor, methylenetetrahydrofolate reductase (NADPH) activity, sodium-exporting ATPase activity, phosphorlyative mechanism, bile acid-exporting ATPase activity, and flap endonuclease activity each were not observed to be different in the 100 vs. 80 days comparison, then up-regulated in the 110 vs. 80 and 110 vs. 100 days comparisons. In contrast to the above, PCNA complex was highly impacted and down-regulated in the 100 vs. 80 days comparison, but not observed to be different in the other comparisons.

The Gene Set Enrichment Analysis (GSEA) generated many pathways that were enriched in either the 80, 100 or 110 days samples (Additional File 4). From these results, cell cycle, vascular smooth muscle contraction, and long-term potentiation were inhibited and enriched in the 100 vs. 80 days comparison (Additional File 4). Particularly, the expression of genes down-regulated in the 100 vs. 80 days comparison was enriched in GnRH signaling pathway (Additional File 2: Sheet ‘DIA KEGG’; Additional File 3). In addition, the expression of genes that were downregulated in the 110 vs. 80 days comparison may be associated with activities such as ECM-receptor interaction, focal adhesion, and spliceosome (Additional File 2: Sheet ‘DIA KEGG’).

Gene network analysis
This analysis focused on uncovering relationships between transcription factors and all the DEGs by means of the IPA knowledgebase, and specifically on published evidence at the level of gene expression (E), transcription (T), and protein-DNA interactions (PD) (Figs. 5–7). In the comparison of 100 vs. 80 days (Fig. 5), this analysis identified transcriptional networks encompassing 148 DEG and 70 transcription factors (67 transcription regulators and 3 ligand-dependent nuclear receptors). Similarly, the comparison of 110 vs. 80 days (Fig. 6) revealed 105 DEG and 74 transcription factors (no ligand-dependent nuclear receptors). The comparison of 110 vs. 100 days (Fig. 7) uncovered 33 DEG and 58
transcription factors (54 transcription regulator and 4 ligand-dependent nuclear receptors).

**Discussion**

Lactogenesis: general considerations

The primiparous gilts used in this study had an average expected gestation length of approximately 114 days. As such, 80 days of gestation represents a time when the gland is starting to undergo a dramatic increase in the rate of growth. At 100 days of gestation, or 14 days prepartum, the gland has increased in mass significantly, increased in total gland protein and decreased in total gland adipose relative to 80 days. The 110 days tissue represents about 90 days, suggests that the start of the stage I occurs between those times. This is followed by a further increase in lipid droplets and endoplasmic reticulum in the epithelial cells from the porcine mammary gland at 105 days of gestation, but not 90 days, during parturition. The initial stage of lactogenesis also coincides in part with the period of colostrum accumulation. During stage I there is an increase in the cellular organelles associated with synthesis of milk components (eg, Golgi apparatus, ribosomes, endoplasmic reticulum; Fig. 8). The presence of these cellular organelles in epithelial cells of pregnant gilts, while remaining relatively constant up to 90 days of gestation, then increases rapidly by 105 days and continues to increase at least through parturition. Furthermore, the rate of incorporation of acetate into lipid in mammary tissue cultures, a reflection of fatty acid synthesis, increases between 90 and 105 days, and then continues to increase at least to 112 days. Collectively, these observations are consistent with stage I of lactogenesis starting between 90
Figure 5. Transcriptional networks encompassing 148 DEG and 70 transcription factors (67 transcription regulators and 3 ligand-dependent nuclear receptors) generated by Ingenuity Pathway Analysis® using the list of DEG in the comparison of 100 vs. 80 d. The analytical approach was set to uncover relationships between transcription factors and all the DEGs in the comparison combined (with expression [denoted by E in the edge of the line], transcription [T], and protein-DNA interactions [PD]). The transcription factors are denoted by large bold fonts. The shapes are filled with red when consistently up-regulated and green when consistently down-regulated at 100 vs. 80 d. Arrows denote the direction of the interaction and solid lines denote direct and dashed lines indirect interactions.

and 105 days of gestation in the sow and continuing up to parturition. Stage II of lactogenesis, referred to as copious milk secretion, occurs starting at or immediately after parturition in the sow. Changes in composition of mammary secretions from a few hours prior to parturition through several days postpartum confirm that stage II of lactogenesis does not occur until parturition in this species.\textsuperscript{30,31}

In the present study, gene expression profiles in mammary tissue collected at 80 days of gestation reflect a growing gland that has not yet started stage I of lactogenesis, while at 100 days the tissue has initiated stage I, and at 110 days of gestation the tissue has fully entered into stage I. The precise timing of the start of stage I of lactogenesis in swine remains to be determined. Mechanistically, our analysis suggests that the marked increase in lipid droplet synthesis was driven by the sustained activation of ‘fatty acid biosynthesis’, ‘Tricarboxylic acid cycle (TCA) cycle’, and ‘glyoxylate and dicarboxylate’ flux, with a modest activation of ‘oxidative phosphorylation’ (Additional Files 1–2). Those results agree with quantitative measurements of acetate and glucose use as energy sources and also for synthesis of lipid during 75 through 105 days of pregnancy,\textsuperscript{6} ie, decrease in oxidation of both compounds coupled with increased use for lipogenesis particularly acetate.

**Immune system**

Both hormonal and local mammary gland factors are involved in control of immunoglobulin transport in the ruminant mammary gland.\textsuperscript{32} The induction of protein export observed at 110 vs. 80 and 110 vs. 100 days (Fig. 8) suggests that genes responsive to
those hormones also might be part of the mechanism that enhance immune-related protein accumulation before farrowing. In the context of immune function and mammary development, the dramatic activation of ‘IL-4 receptor binding’ and ‘Positive regulation of isotype switching to IgE isotypes’ at 110 vs. 80 compared with 100 vs. 80 days (Fig. 8) was driven by the marked upregulation of IL-4 observed at 110 vs. 80 and 110 vs. 100 days (Tables 2 and 3). This cytokine is produced primarily by lymphocytes, suggesting that those cells are part of the mammary tissue “microenvironment” during pregnancy.

Although we are unaware of similar measurements in livestock species, a recent study revealed that IL-4 concentration in lactating mice was very low relative to other cytokines such as TNF, several interleukins, and several chemokines. Because it has been established that IL-4 induces epithelial cell proliferation in vitro via activating MAPK (including JNK), the high expression of this cytokine as well as the activation of the MAPK pathway (Fig. 3) in mammary tissue during late-pregnancy suggest that it could play a role in the late stages of mammary development.

Although the concentration of IgE in milk is very low, another potential biological role for the upregulation of IL-4 might be related with the synthesis of IgE by mononuclear cells that may form part of the mammary microenvironment. Synthesis of IgE requires T and B cell contact. Naïve B cells undergo class switching leading to the development of memory B cells and plasma cells that produce IgE. Antibodies for IgE are involved in the host defense against some types of infection.
observed responses seem to suggest the infiltration of IgE-producing memory B cells into the mammary gland at a point in which the functional differentiation of the mammary gland seems to be nearly complete. It remains to be determined if the marked activation of IgE isotype switching has a functional role, eg, to expedite the re-encounter with antigen.\textsuperscript{40}

From a functional standpoint the high impact and marked activation of ‘IL-4 receptor binding’ seems to be mechanistically related with IgE switching, because IL-4 is a key regulator of that process and also of B-cell proliferation.\textsuperscript{41} It might be possible that the marked activation of the immune system observed close to farrowing serves to provide protection to the mammary gland from potential pathogens.

**Metabolism**

Our finding of ‘lipid’ metabolism as being highly-impacted on day 100 vs. 80 and 110 vs. 80 (Fig. 2) and the marked upregulation (Additional File 1, Tables 1 and 2) of \textit{VLDLR}, \textit{FABP1}, \textit{SLC2A6}, \textit{BTN1A1}, \textit{ACACA}, \textit{ABC G2}, \textit{IDH2}, \textit{ACO2}, and \textit{FBP1} underscored the degree of coordination of several key pathways that would allow for use of long-chain fatty acids from the circulation (\textit{VLDLR}, \textit{FABP1}) but also lipogenic substrates (\textit{SLC2A6}) by mammary cells. The combined data suggested a greater flux via the TCA cycle (\textit{ACO2}, \textit{IDH2}), lipogenesis via \textit{ACACA}, glyceroneogenesis to provide glycerol-3-phosphate (\textit{FBP1}), lipid-droplet associated proteins (\textit{BTN1A1}) to complete the formation of milk fat, and lastly the transport of lipid droplets into the gland cistern (\textit{ABCG2}).\textsuperscript{42-45} Although not all these genes are targets of \textit{PPARG} (eg, \textit{ACACA}, \textit{FABP1}, \textit{ABCG2}), its upregulation (Figs. 5 and 6; Additional File 1) at 100 and 110 days likely elicited a degree of control over the milk fat synthesis process.\textsuperscript{46} Together, these data agree with biochemical studies performed several years ago and outlined in the introductory section.
Although we are unaware of quantitative measures of amino acid (AA) metabolism in mammary tissue during late pregnancy, our data indicated that the inhibition of AA metabolism observed at 110 vs. 80 relative to 100 vs. 80 days was associated with reduced degradation of Essential Amino Acids (EAA) such as Lys, Val, Leu, and Ile, and also reduced ‘Glutathione’, ‘Propanoate’, ‘Selenoamino acid’, ‘Arginine and Proline’, and ‘Glycine, Serine, and Threonine’ metabolism (see Additional File 2: Sheet ‘DIA KEGG’ for details; see also Fig. 8). From a functional standpoint, an inhibition of ‘Glutathione metabolism’ would allow for sparing use of NADPH for fatty acid synthesis and re-synthesis of methionine from 5,10-methylene tetrahydrofolate via MTHFR (Tables 2 and 3), ie, both pathways use NADPH. More importantly, because AA can feed carbon into the TCA cycle or can be used for tissue (parenchyma) and colostrum protein synthesis, the observed adaptations could indicate that the swine mammary gland shifts the priority of AA utilization from greater use/catabolism in early pregnancy, eg, to sustain parenchymal growth, to sparing AA catabolism near parturition either for colostrum synthesis or fetal utilization. The inhibition of ‘Propanoate metabolism’ at 110 vs. 100 days relative to other time comparisons, in particular, suppression of ‘Propanoate metabolism’ at 110 vs. 100 days compared to 110 vs. 80 days, indicates that the swine mammary gland shifts the priority of AA utilization from greater use/catabolism in early pregnancy, eg, to sustain parenchymal growth, to sparing AA catabolism near parturition either for colostrum synthesis or fetal utilization. The inhibition of ‘Propanoate metabolism’ at 110 vs. 100 days relative to other time comparisons, in particular, sup-
ports the view of a gradual decrease in use of AA for catabolism. This pathway encompasses the oxidative deamination of glutamate to alpha-ketoglutarate and ammonia via the key enzyme GLUD1, leading to an increased flux through the TCA cycle and an overall increase in ATP production.\(^\text{47}\)

The estimated daily gain of fetal crude protein is 4.6 g/fetus/day between day 70 of gestation and farrowing, during which the rate of crude protein deposition in each mammary gland is 3.4 g/day.\(^\text{4}\) In fact, the use of EAA for both fetal and mammary tissue crude protein deposition increases dramatically between day 80 of pregnancy to farrowing. Such response is particularly evident for Leu, Lys, Val, Thr, Ile, and Arg,\(^\text{49}\) and could partly explain the activation of ‘Valine, Leucine, and Isoleucine’ and ‘Lysine’ degradation at 100 vs. 80 days relative to 110 vs. 100 days (see Additional File 2: Sheet ‘DIA KEGG’ for details; also Additional File 3 for pathway details). Thus, in the context of our study, the marked transcriptional changes observed between 100 and 110 vs. 80 days provide a window into the mechanisms that drive the functional differentiation of mammary gland from the non-lactating to the lactating state.

A novel finding of our study was the marked activation of ‘Galactose metabolism’ at 100 vs. 80 days, a response driven primarily by the marked upregulation of \textit{UGP2} (UDP-glucose pyrophosphorylase) and \textit{AKR1B1} (aldo-reductase) (Tables 1 and 2) coupled with the downregulation of \textit{LCT} (lactase) and \textit{B4GALT1} (Additional Files 1 and 3). Based on the evaluation of the KEGG pathway our data would suggest greater UDP-glucose and D-galactose production but lower D-lactose (Additional File 3). The ultimate fate of D-galactose, particularly at 100 vs. 80 days, could have been its metabolism through glycolysis as a source of energy. However, the marked upregulation of \textit{LALBA} (Tables 2 and 3) at 110 vs. 80 and 100 days and the downregulation of \textit{UGP2} (namely at 110 vs. 100 days) likely resulted in greater lactose synthesis. Although not measured in earlier studies, it is likely that the observed accumulation of secretory products in alveoli of mammary tissue at 105 days of gestation also is driven by lactose synthesis such that by ∼110 to ∼112 days of parturition expression of genes such as \textit{LALBA} is up-regulated. The inhibition of ‘Galactose’, ‘Starch and sucrose’, and ‘Glyoxylate and dicarboxylate’ metabolism at 110 vs. 100 days compared with 110 vs. 80 days might have been associated with the insulin-resistant state of pregnancy to support the marked rate of fetal growth at the latter stages of pregnancy.\(^\text{50}\)

The fact that there was a decrease in the impact and a lack of change in flux for most metabolic pathways at 110 vs. 100 days (Fig. 1 and Additional File 2: Sheet ‘KEGG Summary’) seems to suggest that other molecular adaptations take precedence during the immediate time preceding parturition, ie, help “complete” the transition of the tissue to “fully-functional” gland or from stage 1 to stage 2 of lactogenesis. That was particularly evident when exploring the overall impact and flux of most pathways associated with GIP, EIP, CP, and OS in the KEGG database.

**Cellular communication**

The mammary gland experiences repeated cycles of pregnancy, lactation, and involution. During these cycles, the interactions of mammary epithelial cells with their surrounding extracellular matrix (ECM), particularly the basement membrane and the connective tissue, play a pivotal role in building a communication bridge between epithelial cells and their surrounding environment.\(^\text{51,52}\) In rat cervical stromal cells it was demonstrated that \textit{ITGA11} and \textit{ITGA2} expression increases through most of the pregnancy and decreases along with progesterone as the time of parturition nears.\(^\text{53}\) The functions of \textit{ITGA11} include fluid homeostasis by maintaining ECM tension and inhibition of cell migration;\(^\text{55}\) hence, upregulation of \textit{ITGA11} expression during pregnancy may help prevent excessive tissue remodeling, whereas the decrease close to parturition may serve to enhance influx of inflammatory cells and fluid.\(^\text{53}\) The upregulation of collagen genes (Table 1), vitronectin (VTN), and \textit{ITGA11} (Additional File 1) and the lack of change in laminin at 100 vs. 80 days (Additional File 3) seem to agree with the data from pregnant rats. However, at 110 vs. 80 days the downregulation of collagen (Tables 4 and 5; Additional File 3) coupled with upregulation of \textit{ITGA11} and \textit{ITGB4} (Additional File 1) suggests that these integrins may play a different role in the mammary gland. For instance, they may protect against excessive tissue remodeling via the upregulation of matrix metalloproteinases (eg, \textit{MMP1}; Additional File 1), which are involved in col-
lagn digestion and breakdown of the extracellular matrix.\textsuperscript{56}

Junctional complexes including tight junctions (TJs), adherens junctions (AJs), and gap junctions serve an important role in mediating cell–cell interactions.\textsuperscript{57} The importance of gap junctions in the proper development, differentiation and proliferation of the mammary gland has been known for some time.\textsuperscript{58–61} Within gap junctions there are intercellular channels that allow direct communication between cells, allowing for direct transport of small molecules such as ions, amino acids, and other metabolites.\textsuperscript{62} These constitute normal physiological processes between adjacent cells. Thus, the marked increase in activation of gap junction (Fig. 8; Additional File 1) is in accordance to well-established knowledge of the underlying physiological events.\textsuperscript{63}

Mammary gland tight junctions are permeable but experience closure around farrowing in the pregnant animal.\textsuperscript{64} In turn, the closure of tight junctions around parturition is often accompanied by a decrease in some ions such as sodium and chloride, and an increase in lactose and potassium in milk.\textsuperscript{65} The drop in progesterone prior to parturition is also responsible for the closure of mammary tight junctions in the late-pregnant mouse.\textsuperscript{66} Thus, the observation of a modest activation of genes associated with tight junctions at 110 vs. 100 days (Fig. 8) supports the role of progesterone during late-pregnancy.

### Signaling regulation

The induction of Gonadotropin-releasing hormone (GnRH) signaling during pregnancy (Fig. 3) is similar to what was observed recently in bovine mammary gland, and suggests this novel mechanism might be conserved among mammals. Expression of GnRH receptor (GnRHR), which allows for GnRH signaling and synthesis of gonadotropins in the anterior pituitary, also occurs in the mammary gland.\textsuperscript{67} The function of GnRHR in extrapituitary tissues is not clear, but it could play a role in reducing cell proliferation.\textsuperscript{67} Many hormones have been detected in milk but not Leutenizing hormone (LH) or follicle stimulating hormone (FSH).\textsuperscript{68} Further studies are required to clarify these findings.

Previous in vivo data from the bovine mammary gland\textsuperscript{23,69} clearly indicated that mTOR plays an important role in milk protein synthesis. The marked induction of the mTOR signaling pathway (Fig. 3) was unexpected because this pathway changed little during late-pregnancy in the bovine mammary gland\textsuperscript{23} and, in fact, there was a small degree of inhibition of this pathway during early lactation. In a recent microarray study of the swine mammary gland, a pathway analysis indicated that few genes composing the mTOR pathway were upregulated on day 17 compared with day –17 around parturition.\textsuperscript{11} Although at a different stage of the lactation cycle (ie, non-lactating mammary), the present data on ribosome, Golgi apparatus, amino acid metabolism (eg, His, Lys), and mTOR signaling (Fig. 3) suggest an important role of this pathway in preparing the mammary gland for active milk protein synthesis.\textsuperscript{69}

### Blood flow regulation

An increase in mammary blood flow is observed concurrently with the fall in progesterone close to parturition, and is thought to be a physiological adaptation to increase volume of secretions within the gland.\textsuperscript{70} At a more basic level, the control of blood volume through vessels is closely regulated via contraction and relaxation of vascular smooth muscle cells (VSMC) at least in part via signaling through adrenergic receptors or intracellular Ca\textsuperscript{2+} concentration.\textsuperscript{71,72} The fact that vascular smooth muscle contraction was activated at 100 and 110 vs. 80 days (Supplementary File 2, sheet DIA KEGG) seems to argue against a role of Ca\textsuperscript{2+} signaling. It is also possible that estrogen and relaxin might play an inhibitory role on VSMC function (ie, proliferation and contraction).\textsuperscript{73,74}

There was little change observed in the angiogenesis pathway (Fig. 8), and the increase in activation of Ca\textsuperscript{2+} signaling observed at 110 vs. 100 days was modest compared with the marked increase in VEGF and MAPK signaling (Fig. 3). In that context, the fact that ‘positive regulation of endothelial cell differentiation’ was substantially inhibited (Additional File 2, sheet GOTERM BP) and ‘endothelial cell migration’ was markedly activated at 110 vs. 80 days compared with 110 vs. 100 days seems to suggest that the effect of VEGF signaling on VSMC of the mammary gland during the late stages of pre-partum mammary development is to promote endothelial cell migration rather than formation of new blood vessels.\textsuperscript{75} The marked increase in the activation of MAPK signaling\textsuperscript{76} also supports a functional role of VEGF in the formation and migration of endothelial cells within the mammary gland.
Epigenetic regulation and transcription
As opposed to what was recently observed in mature bovine mammary gland,23 our data revealed a marked and sustained activation of the components of epigenetic modification (euchromatin and nuclear euchromatin; Fig. 8) during late-pregnancy. Those data, however, contrast with the lower-impact and activation of the GO terms ‘chromatin assembly or disassembly’ and ‘chromatin remodeling’ on day 100 and 110 along with the marked inhibition of ‘chromatin-mediated maintenance of transcription’ on day 110 vs. 80 (Additional File 2, sheet GOTERM BP). The pattern of activation of euchromatin at 100 and 110 vs. 80 days was in line with the small change in the total number of DEG (Fig. 1) but the large increase in tissue DNA content (Fig. 8) at both time points. Interestingly, there were fewer DEG at 110 vs. 100 days, which corresponds to the lack of change in tissue DNA content between both times, and potentially with the fact that the GO term ‘chromatin-mediated maintenance of transcription’ was markedly inhibited between 100 to 110 vs. 80 days and was not impacted at all on day 110 vs. 100.

The above changes, along with the marked and progressive activation of the GO term ‘positive regulation of transcription factor activity’, suggest an active degree of transcription through at least 100 days of pregnancy. By 110 days, however, the continued development of the mammary gland as discerned by the increase in cross sectional area (Fig. 8) and previous physiological data2 would have been driven at least in part by activation of genes associated with DNA replication, cell cycle, and cell growth (Figs. 3 and 8). Overall, results highlight a seemingly crucial role of epigenetic regulation and transcription factor activity in swine mammary development during pregnancy. Such a role has been reported to exist in the lactating bovine mammary gland.77

Gene networks
The consistent downregulation of the transcription regulators TP53, ARNT2, EGR1, HDAC1, and E2F4 coupled with the upregulation of PPARG, EPAS1, and KLF9 on day 100 and/or 110 compared with day 80 underscored their potential importance in the local control of swine mammary development at the latter stages of pregnancy (Figs. 5 and 6). Furthermore, from a functional standpoint the upregulation at day 110 vs. 100 of the transcription factors GABPA, which controls expression of oxytocin receptor (OXTR) and prolactin (PRL), and STAT5B, which controls milk protein synthesis, appear quite important at the closest point to parturition that we studied (Fig. 6). Although we are unaware of similar data in pig mammary gland, previous work in bovine indicated that TP53 and HDAC1 are primarily expressed in parenchymal than fat pad tissue, but PPARG, KLF9, EGR1, EPAS1 are primarily expressed in fat pad.26 It also can be deduced from mammary tissue studies in dairy cattle26,78 that ARNT2, NR3C1, and ETV1 are likely preferentially expressed in parenchyma as opposed to the fat pad.

The apparent role of TP53 networks in mammary gland development is not entirely surprising because this transcription regulator has been well-studied in the context of cancer, where its inhibition leads to cell cycle progression and eventually neoplastic transformation.79 Furthermore, E2F4 plays an important role in the control of cell cycle and the action of tumor suppressor proteins, causing an overall decrease in expression of proliferation-associated genes.80 It was also recently demonstrated that nuclear E2F4, when unregulated, plays a key role in the downregulation of several mitotic genes, hence, promoting cell cycle arrest.81 Therefore, in the context of mammary development, the downregulation of TP53 and E2F4 along with the observed levels of expression of its target genes could be functionally related to cellular proliferation (eg, greater activation of the cell cycle pathway; Figs. 5 and 6) and the morphological changes that were observed between day 80 and 110 (Fig. 8).

A recent study clearly established that the role of TP53 in enhancing cell-cycle arrest is mediated at the transcriptional level.82 Whereas the role of TP53 appears clear at both 100 and 110 days, the activation of several signaling pathways known to promote cell differentiation (eg, Jak-STAT, Hedgehog signaling; Fig. 3) and cell growth (mTOR signaling) were markedly activated at 110 vs. 100 days suggesting they may play a more important role in the latter stages of pregnancy and in the case of mTOR signaling may even be important for the complete activation of the milk protein synthesis machinery.59 Further support for the functional role of TP53 at the transcription level is the recent demonstration that its activation results in the inhibition of the mTOR
pathway and consequently a repression of protein translation.\textsuperscript{82}

Although much less is known about the functional role in mammary development of several transcription regulators that we uncovered, eg, \textit{DEAF1}, \textit{MECP2}, \textit{RARB}, \textit{EGR1}, \textit{ETV1}, and \textit{EPAS1}, the fact that they experienced marked upregulation or downregulation depending on day of pregnancy suggests that they are important. For instance, recent studies revealed that 17\textbeta-estradiol increased the expression of \textit{DEAF1} in vitro,\textsuperscript{83} which in turn could downregulate serotonin signaling\textsuperscript{84} leading to a potential impairment in milk secretion.\textsuperscript{85} The fact that \textit{DEAF1} was markedly upregulated (\textasciitilde6-fold) at 110 vs. 80 days supports its role in the process of lactogenesis. \textit{EPAS1} is a transcription factor that induces genes regulated by oxygen, ie, it is induced when cellular oxygen levels fall, and, for instance, it has been demonstrated to play a role in the proliferation-promoting effect of HIF2A, partly through enhancing mTOR signaling.\textsuperscript{86} The role of \textit{RARB} in limiting cell growth by regulating gene expression is well-established;\textsuperscript{87} thus, it could be envisioned that it forms part of the network controlling mammary cell proliferation.

A novel and seemingly important finding in this study was the marked upregulation of \textit{MECP2} on day 100 and 110 vs. 80, which encodes a nuclear protein that possesses a methyl-CpG binding domain; thus, it is capable of binding specifically to methylated DNA.\textsuperscript{88} This protein functions primarily as a transcriptional repressor. Although the 5-hydroxymethylcytosine (5 hmc) and 5-methylcytosine content in the mammary gland genome is unknown, it has been shown in neuronal cells containing high levels of 5 hmc that \textit{MECP2} is the major methyl-CpG-binding protein.\textsuperscript{89} Because mutations that inhibit 5 mhC binding are known to cause disease, it is tempting to speculate that in the pregnant swine mammary gland of primiparous animals this nuclear protein may serve as one of the epigenetic mechanisms for regulating euchromatin structure and gene expression. A recent review discussed the role of epigenetics in regulation of bovine mammary function.\textsuperscript{90}

**Conclusions**

The present bioinformatics and gene network functional analysis of the swine mammary transcriptome strengthens the understanding of the biological adaptations occurring in this organ during late gestation. The data underscored a novel role for IL-4 in mammary development during pregnancy. Several elements across a wide number of pathways were identified as potential regulatory factors of the local adaptations in mammary gland. Further research will help confirm the functional relevance of the pathways uncovered, and how they can be manipulated to control sow milk yield and quality.

**Author Contributions**

Conceived and designed the experiment: WLH. Conceived and performed the analyses: WZ, KS, MJ, DEG, SLR, JJL. Wrote the manuscript: WZ, KS, WLH, JJL. Agree with manuscript results and conclusions: WZ, KS, MJ, DEG, JL, WLH, SLR, JJL. Jointly developed the structure and arguments for the paper: WZ, WLH, JJL. Made critical revisions and approved final version: WZ, KS, MJ, DEG, JL, WLH, SLR, JJL. All authors reviewed and approved of the final manuscript.

**Funding**

Author(s) disclose no funding sources.

**Competing Interests**

Author(s) disclose no potential conflicts of interest.

**Disclosures and Ethics**

As a requirement of publication the authors have provided signed confirmation of their compliance with ethical and legal obligations including but not limited to compliance with ICMJE authorship and competing interests guidelines, that the article is neither under consideration for publication nor published elsewhere, of their compliance with legal and ethical guidelines concerning human and animal research participants (if applicable), and that permission has been obtained for reproduction of any copyrighted material. This article was subject to blind, independent, expert peer review. The reviewers reported no competing interests.

**References**

1. Boyd RD, Kensinger RS. Metabolic precursors for milk synthesis. In: Verstegen MWA, Moughun PJ, Schrama JW, editors. The Lactating Sow. 1998; Wageningen: Wageningen Press.
2. Sorensen MT, Sejrsen K, Purup S. Mammary gland development in gilts. Livest Prod Sci. 2002;75:143–8.
3. Ji F, Hurley WL, Kim SW. Characterization of mammary gland development in pregnant gilts. J Anim Sci. 2006;84:579–87.
4. Kim SW, Hurley WL, Han IK, Easter RA. Changes in tissue composition associated with mammary gland growth during lactation in sows. J Anim Sci. 1999;77:2510–16.

5. Hurley WL, Doane RM, O’Day-Boon BM, Winn RJ, Mojonier LE, Sherwood OD. Effect of relaxin on mammary development in ovario- mized pregnant gilts. Endocrinol. 1991;128:1285–90.

6. Kensinger RS, Collier RJ, Bazer FW, Duscay CA, Becker HN. Nucleic acid, metabolic and histological changes in gilt mammary tissue during pregnancy and lactogenesis. J Anim Sci. 1982;54:1297–308.

7. Tramontana S, Bionaz M, Sharma A, et al. Internal controls for quantitative polymerase chain reaction of swine mammary glands during pregnancy and lactation. J Dairy Sci. 2008;91:3057–66.

8. Bionaz M, Loor JJ. Ruminant metabolic systems biology: reconstruction and integration of transcriptome dynamics underlying functional responses of tissues to nutrition and physiological state. Gene Regul Syst Biol. 2012;6:109–25.

9. Fontanesi L, Galimberti G, Calo DG, et al. Microarray gene expression analysis of porcine skeletal muscle sampled at several post mortem time points. Meat Sci. 2011;88:604–9.

10. Brugemann FJ, Westerhoff HV. The nature of systems biology. Trends Microbiol. 2007;15:45–50.

11. Shu DP, Chen BL, Hong J, et al. Global transcriptional profiling in porcine mammary glands from late pregnancy to peak lactation. OMICS. 2012;16:123–37.

12. Kanehisa M, Araki M, Goto S, et al. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2008;36:D480–4.

13. Bionaz M, Periasamy K, Rodriguez-Zas SL, Hurley WL, Loor JJ. A novel dynamic impact approach (DIA) for functional analysis of time-course omics studies: validation using the bovine mammary transcriptome. PLoS One. 2012;7:e32455.

14. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1–13.

15. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27–30.

16. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:P3.

17. O’Day MB, Winn RJ, Easter RA, Dziuk PJ, Sherwood OD. Hormonal control of the cervix in pregnant gilts. II. Relaxin promotes changes in the physical properties of the cervix in ovariectomized hormone-treated pregnant gilts. Endocrinol. 1989;125:3004–10.

18. Zhao SH, Recknor J, Lunney JK, et al. Validation of a first-generation long-oligonucleotide microarray for transcriptional profiling in the pig. Genomics. 2005;86:618–25.

19. Loor JJ, Everts RE, Bionaz M, et al. Nutrition-induced ketosis alters metabolism and histological changes in gilt mammary tissue during pregnancy and lactogenesis. J Anim Sci. 1982;54:1297–308.

20. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215:403–10.

21. Quackenbush J, Liang F, Holt I, Pertea G, Upton J. The TIGR gene indices: reconstruction and representation of expressed gene sequences. Nucleic Acids Res. 2000;28:141–51.

22. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate—a Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc B Met. 1995;57:289–300.

23. Bionaz M, Periasamy K, Rodriguez-Zas SL, et al. Old and new stories: revelations from functional analysis of the bovine mammary transcriptome during the lactation cycle. PLoS One. 2012;7:e33268.

24. Huang da W, Sherman BT, Lemppicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57.

25. Kanehisa M, Goto S, Hattori M, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 2006;34:D354–7.

26. Piantoni P, Bionaz M, Graugnard DE, et al. Functional and gene network analyses of transcriptional signatures characterizing pre-weaned bovine mammary parenchyma or fat pad uncovered novel inter-tissue signaling networks during development. BMC Genomics. 2010;11:331.
52. Prince JM, Klimowska TC, Marshman E, et al. Cell-matrix interactions during development and apoptosis of the mouse mammary gland in vivo. Dev Dyn. 2002;223:497–516.

53. Ji H, Long V, Briody V, Chien EK. Progesterone modulates integrin [alpha]2 [ITGA2] and [alpha]11 (ITGA11) in the pregnant cervix. Reprod Sci. 2011;18:156–63.

54. Svendsen OS, Barczyk MM, Popova SN, Lidén A, Gullberg D, Wig H. The alpha1beta1 integrin has a mechanistic role in control of interstitial fluid pressure and edema formation in inflammation. Arterioscler Thromb Vasc Biol. 2009;29:1864–70.

55. Popova SN, Rodríguez-Sánchez B, Lidén A, Betsholtz C, Van Den Bos T, Gullberg D. The mesenchymal alpha1beta1 integrin attenuates PDGF-BB-stimulated chemotaxis of embryonic fibroblasts on collagens. Dev Biol. 2004;270:427–42.

56. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:201–12.

57. Itoh M, Bissell MJ. The organization of tight junctions in epithelia: Implications for mammary gland biology and breast tumorigenesis. J Mammary Gland Biol Neoplasia. 2003;8:449–62.

58. Loewenstein WR. Junctional intercellular communication and the control of growth. Biochim Biophys Acta. 1979;560:1–65.

59. Trosko JE. Hierarchical and cybernetic nature of biologic systems and their functions in the pregnant cervix. J Physiol-London. 1974;243:129–51.

60. Nishikawa S, Moore RC, Nonomura N, Oka T. Progesterone and EGF inhibit mouse mammary-gland prolactin receptor and beta-casein gene expression. Am J Physiol. 1994;267:C1467–72.

61. Aguilar-Rojas A, Huerta-Reyes M. Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-embryonic tissues and cancer cells. Oncol Rep. 2009;22:981–90.

62. Grosvenor CE, Picciano MF, Baumrucker CR. Hormones and growth factors in milk. Endocr Rev. 1993;14:710–28.

63. Bionaz M, Loret JI. Gene networks driving bovine mammary protein synthesis during the lactation cycle. Bioinform Biol Insights. 2011;5:83–98.

64. Burd LL, et al. The relationship of changes in mammary blood flow and plasma progestrone at the time of parturition in the ewe. Am J Obstet Gynecol. 1978;132:385–91.

65. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 1995;75:487–517.

66. Karaki H, Ozaki H, Hori M, et al. Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev. 1997;49:157–230.

67. Tostes RC, Nigro D, Fortes ZB, Carvalho MH. Effects of estrogen on the vascular system. Braz J Med Biol Res. 2003;36:1143–58.

68. Min G, Sherwood OD. Identification of specific relaxin-binding cells in the cervix, mammary glands, nipples, small intestine, and skin of pregnant pigs. Biol Reprod. 1996;55:1243–52.

69. Risau W, Flammé I. Vasculogenesis. Annu Rev Cell Dev Biol. 1995;11:73–91.

70. Kobayashi I, Semba S, Matsuda Y, Kuroda Y, Yokozaki H. Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma. Pathobiol. 2006;73:8–17.

71. Singh K, Erdman RA, Swanson KM, et al. Epigenetic regulation of milk production in dairy cows. J Mammary Gland Biol Neoplasia. 2010;15:101–12.

72. Meyers K, Drackley J, Morin D, et al. Gene network and pathway analysis of bovine mammary tissue challenged with Streptococcus uberis reveals induction of cell proliferation and inhibition of PPARgamma signaling as potential mechanism for the negative relationships between immune response and lipid metabolism. BMC Genomics. 2009;10:542.

73. Bieging KT, Attardi LD. Deconstructing p53 transcriptional networks in tumor suppression. Trends Cell Biol. 2012;22:97–106.

74. Huang L, Zhao S, Frasor JM, Dai Y. An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors. PLoS One. 2011;6:e22274.

75. Plescia D, Crosby ME, Gupta D, Almasan A. E2F function in G2: maintaining G2-arrest to prevent mitotic entry with damaged DNA. Cell Cycle. 2007;6:1147–52.

76. Loayza-Puch F, Drost J, Rooijers K, Lopes R, Elkon R, Agami R. P53 induces transcriptional and translational programs to suppress cell proliferation and growth. Genome Biol. 2013;14:R32.

77. Adeosun SO, Albert PR, Austin MC, Iyo AH. 17beta-estradiol-induced regulation of the novel 5-HT1A-related transcription factors NUDR and Freud-1 in SH SY5Y cells. Cell Mol Neurobiol. 2004;10:575–93.

78. Collier RJ, Hernandez LL, Horneman ND. Serotonin as a homeostatic regulator of lactation. Dev Mol Endocrinol. 2012;43:161–70.

79. Elorza A, Soro-Arniz I, Meléndez-Rodríguez F, et al. HIF2alpha acts as an mTORC1 activator through the amino acid carrier SLC7A5. Mol Cell. 2012;48:681–91.

80. Hu KW, Chen FH, Ge JF, Cao LY, Li H. Retinoid receptors in gastric function as a homeostatic regulator of lactation. Dev Mol Endocrinol. 2012;43:161–70.

81. Adeosun SO, Albert PR, Austin MC, Iyo AH. 17beta-estradiol-induced regulation of the novel 5-HT1A-related transcription factors NUDR and Freud-1 in SH SY5Y cells. Cell Mol Neurobiol. 2004;10:575–93.

82. Collier RJ, Hernandez LL, Horneman ND. Serotonin as a homeostatic regulator of lactation. Dev Mol Endocrinol. 2012;43:161–70.

83. Adeniran SO, Albert PR, Austin MC, Iyo AH. 17beta-estradiol-induced regulation of the novel 5-HT1A-related transcription factors NUDR and Freud-1 in SH SY5Y cells. Cell Mol Neurobiol. 2004;10:575–93.

84. Albert PR, Lemonde S. 5-HT1A receptors, gene repression, and depression: guilt by association. Cell Mol Neurobiol. 2004;10:575–93.

85. Collier RJ, Hernandez LL, Horneman ND. Serotonin as a homeostatic regulator of lactation. Dev Mol Endocrinol. 2012;43:161–70.

86. Elorza A, Soro-Arniz I, Meléndez-Rodríguez F, et al. HIF2alpha acts as an mTORC1 activator through the amino acid carrier SLC7A5. Mol Cell. 2012;48:681–91.

87. Hu KW, Chen FH, Ge JF, Cao LY, Li H. Retinoid receptors in gastric cancer: expression and influence on prognosis. Asian Pac J Cancer Prev. 2012;13:1809–17.

88. Na ES, Monteggia LM. The role of MeCP2 in CNS development and function. Horm Behav. 2011;59:364–8.

89. Mellen M, Ayata P, Dewell S, Kriaucionis S, Heintz N. MeCP2 binds to 5 hmC enriched within active genes and accessible chromatin in the nervous system. J Dev Biol. 2012;151:1417–30.

90. Singh K, Molenaar AJ, Swanson KM, et al. Epigenetics: a possible role in acute and transgenerational regulation of dairy cow milk production. Animal. 2012;6:375–81.
Supplementary Files
Additional File 1
Additional File 2
Additional File 3
Additional File 4